HSBC raised the firm’s price target on Pfizer (PFE) to $32 from $29 and keeps a Buy rating on the shares. The firm says the uncertain macro backdrop, rising geopolitical risk, and lower exposure to AI disruption risks could attract investors to healthcare and drive outperformance in the coming quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- District court rules federal limits to vaccines not based on science, NYT says
- Mixed options sentiment in Pfizer with shareslittle changed
- Pfizer (PFE) Quietly Arms Pipeline for Next Growth Wave
- Mixed options sentiment in Pfizer with shares down 0.43%
- Pfizer Targets Pediatric Ulcerative Colitis With New Etrasimod Trial: What Investors Should Watch